Molnupiravir final effectiveness

https://www.nytimes.com/2021/11/26/science/merck-molnupiravir-antiviral-covid-pill.html?action=click

REMEMBER to always wait and look at the final analysis because the interim analysis may not have achieved the required number of outcome as estimated in the a priori power analysis.

"Merck’s initial estimate that the drug reduced hospitalization and death by 50 percent came from an early look at results from 775 study participants. The updated figure announced on Friday came from more than 1,400. In the final analysis, the participants who received molnupiravir had a 6.8 percent risk of being hospitalized, and one patient died. Those who received a placebo had a 9.7 percent risk of being hospitalized, and nine died."